AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. It also offers thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. In addition, the company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; and Asclera injection for treating uncomplicated spider and reticular veins of the lower extremities. Further, it provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation system; and radiofrequency ablation products for ablating solid cancerous or benign tumors. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ANGO
CUSIP03475V10
Phone518-795-1400
Debt
Debt-to-Equity Ratio0.16
Current Ratio2.93
Quick Ratio2.08
Price-To-Earnings
Trailing P/E Ratio28.99
Forward P/E Ratio24.94
P/E GrowthN/A
Sales & Book Value
Annual Sales$344.29 million
Price / Sales2.30
Cash Flow$1.3857 per share
Price / Cash15.48
Book Value$14.74 per share
Price / Book1.46
Profitability
EPS (Most Recent Fiscal Year)$0.74
Net Income$16.33 million
Net Margins4.74%
Return on Equity5.21%
Return on Assets3.94%
Miscellaneous
Employees1,145
Outstanding Shares36,890,000
Market Cap$787.51 million
AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions
What is AngioDynamics' stock symbol?
AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."
How were AngioDynamics' earnings last quarter?
AngioDynamics, Inc. (NASDAQ:ANGO) issued its earnings results on Wednesday, July, 11th. The medical instruments supplier reported $0.20 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.21 by $0.01. The medical instruments supplier had revenue of $88.30 million for the quarter, compared to analyst estimates of $89.02 million. AngioDynamics had a return on equity of 5.21% and a net margin of 4.74%. AngioDynamics's revenue for the quarter was up 1.6% compared to the same quarter last year. View AngioDynamics' Earnings History.
When is AngioDynamics' next earnings date?
What guidance has AngioDynamics issued on next quarter's earnings?
AngioDynamics updated its FY19 earnings guidance on Wednesday, July, 11th. The company provided EPS guidance of $0.82-0.86 for the period, compared to the Thomson Reuters consensus estimate of $0.91. The company issued revenue guidance of $344-349 million, compared to the consensus revenue estimate of $347.79 million.
What price target have analysts set for ANGO?
5 equities research analysts have issued 12 month price objectives for AngioDynamics' shares. Their predictions range from $16.33 to $20.00. On average, they expect AngioDynamics' share price to reach $18.1650 in the next year. This suggests that the stock has a possible downside of 15.3%. View Analyst Price Targets for AngioDynamics.
What is the consensus analysts' recommendation for AngioDynamics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AngioDynamics.
Who are some of AngioDynamics' key competitors?
Some companies that are related to AngioDynamics include Merit Medical Systems (MMSI), Irhythm Technologies (IRTC), Nevro (NVRO), Tandem Diabetes Care (TNDM), Glaukos (GKOS), Mazor Robotics (MZOR), Cardiovascular Systems (CSII), Luminex (LMNX), Cryolife (CRY), Atrion (ATRI), AtriCure (ATRC), Tactile Systems Technology (TCMD), OraSure Technologies (OSUR), Orthofix International (OFIX) and Cerus (CERS).
Who are AngioDynamics' key executives?
AngioDynamics' management team includes the folowing people:
- Mr. James C. Clemmer, CEO, Pres & Director (Age 54)
- Mr. Michael C. Greiner, Exec. VP & CFO (Age 45)
- Mr. Stephen A. Trowbridge, Sr. VP, Gen. Counsel & Assistant Sec. (Age 44)
- Mr. Chad T. Campbell, Sr. VP & GM of Vascular Access Global Bus. Unit (Age 47)
- Mr. Robert A. Simpson, Sr. VP & GM of Peripheral Vascular Global Bus. Unit (Age 46)
Has AngioDynamics been receiving favorable news coverage?
News articles about ANGO stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AngioDynamics earned a daily sentiment score of 0.23 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 46.47 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for AngioDynamics.
Who are AngioDynamics' major shareholders?
AngioDynamics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.85%), Dimensional Fund Advisors LP (8.36%), Janus Henderson Group PLC (4.89%), Wells Fargo & Company MN (2.93%), Fort Washington Investment Advisors Inc. OH (2.18%) and Royce & Associates LP (2.12%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, James C Clemmer and Jan Stern Reed. View Institutional Ownership Trends for AngioDynamics.
Which institutional investors are selling AngioDynamics stock?
ANGO stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Fort Washington Investment Advisors Inc. OH, Wells Fargo & Company MN, Lapides Asset Management LLC, Alambic Investment Management L.P., Systematic Financial Management LP, Fenimore Asset Management Inc. and Factorial Partners LLC. View Insider Buying and Selling for AngioDynamics.
Which institutional investors are buying AngioDynamics stock?
ANGO stock was bought by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, BlackRock Inc., EAM Investors LLC, Acadian Asset Management LLC, Segall Bryant & Hamill LLC, EAM Global Investors LLC, Connor Clark & Lunn Investment Management Ltd. and ClariVest Asset Management LLC. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics.
How do I buy shares of AngioDynamics?
Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AngioDynamics' stock price today?
One share of ANGO stock can currently be purchased for approximately $21.45.
How big of a company is AngioDynamics?
AngioDynamics has a market capitalization of $787.51 million and generates $344.29 million in revenue each year. The medical instruments supplier earns $16.33 million in net income (profit) each year or $0.74 on an earnings per share basis. AngioDynamics employs 1,145 workers across the globe.
How can I contact AngioDynamics?
AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]
MarketBeat Community Rating for AngioDynamics (NASDAQ ANGO)
MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe ANGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
